These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18184079)

  • 41. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.
    Dwyer JJ; Wilson KL; Davison DK; Freel SA; Seedorff JE; Wring SA; Tvermoes NA; Matthews TJ; Greenberg ML; Delmedico MK
    Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12772-7. PubMed ID: 17640899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
    Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.
    Leung PH; Chen JH; Wong KH; Chan KC; Lam HY; Cheng VC; Yuen KY; Yam WC
    J Clin Virol; 2010 Mar; 47(3):273-5. PubMed ID: 20116329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 46. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 50. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.
    Trabaud MA; Cotte L; Labernardière JL; Lebel-Binay S; Icard V; Tardy JC; Trepo C; Andre P
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):134-44. PubMed ID: 17621239
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
    Becker Y
    Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 56. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
    Marconi V; Bonhoeffer S; Paredes R; Lu J; Hoh R; Martin JN; Deeks SG; Kuritzkes DR
    J Acquir Immune Defic Syndr; 2008 Aug; 48(5):572-6. PubMed ID: 18645515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
    Wei X; Decker JM; Liu H; Zhang Z; Arani RB; Kilby JM; Saag MS; Wu X; Shaw GM; Kappes JC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1896-905. PubMed ID: 12019106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
    Bai X; Wilson KL; Seedorff JE; Ahrens D; Green J; Davison DK; Jin L; Stanfield-Oakley SA; Mosier SM; Melby TE; Cammack N; Wang Z; Greenberg ML; Dwyer JJ
    Biochemistry; 2008 Jun; 47(25):6662-70. PubMed ID: 18507398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.